Related Experiment Video
Updated: Jan 7, 2026
08:39
Murine Colitis Modeling using Dextran Sulfate Sodium DSS
Published on: January 19, 2010
50.8K
Selective STAT3 Allosteric Inhibitors HCB-5300 and HCB-5400 Alleviate Dextran Sulfate Sodium-Induced Ulcerative
Wook-Young Baek1, Ji-Won Kim1, So-Won Park2
1Department of Rheumatology, Ajou University School of Medicine, Suwon 16499, Republic of Korea.
International Journal of Molecular Sciences
|December 30, 2025
Summary
Novel STAT3 inhibitors, HCB-5300 and HCB-5400, effectively reduced inflammation and damage in a mouse model of inflammatory bowel disease (IBD). HCB-5400 demonstrated superior efficacy, highlighting its therapeutic potential for IBD flares.
Area of Science:
- Pharmacology
- Gastroenterology
- Immunology
Background:
- Inflammatory bowel disease (IBD) involves chronic gastrointestinal inflammation and damage.
- STAT3 signaling is a key pathway implicated in IBD pathogenesis.
Purpose of the Study:
- To evaluate the efficacy of novel selective STAT3 allosteric inhibitors, HCB-5300 and HCB-5400, in a dextran sulfate sodium (DSS)-induced ulcerative colitis mouse model.
- To assess the anti-inflammatory effects and therapeutic potential of these inhibitors in IBD.
Main Methods:
- Ulcerative colitis was induced in C57BL/6 mice using 3% DSS.
- Mice were treated orally with HCB-5300 (25 mg/kg) or HCB-5400 (12.5 mg/kg) during DSS induction.
- Disease activity index (DAI), colon length, histopathology, and IL-6 levels were assessed.
Main Results:
- Both HCB-5300 and HCB-5400 significantly mitigated DSS-induced colitis, reducing body weight loss and improving DAI scores.
- Treatment preserved colon length and decreased mucosal damage and inflammation, with lower IL-6 levels observed.
- HCB-5400 showed superior efficacy across most evaluated parameters.
Conclusions:
- HCB-5300 and HCB-5400 are potent, selective STAT3 allosteric inhibitors with significant anti-inflammatory effects.
- HCB-5400 demonstrates promising therapeutic potential for managing inflammatory flares in IBD.
- These findings support further investigation of STAT3 allosteric inhibitors for IBD treatment.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
413
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
413
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
402
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
402
01:29Inflammatory Bowel Disease IV: Pharmacological Management
427
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
427
01:17Drugs for Treatment of Diarrhea-Predominant IBS
590
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
590